drugset / Trial / NCT02577107
Head to Head Study of Anti-VEGF Treatment.
RandomizedParallel-groupOpen-labelBasic science
Summary
An exploratory single site, open label, randomized, controlled study evaluated plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab (Lucentis) and conbercept (Langmu) for neovascular age-related macular degeneration
Timeline
- Start
- 2016-01-13
- Primary completion
- 2016-07-09
- Completion
- 2016-07-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Conbercept | Protein / enzyme biologic | 0.5 mg | Intravitreal |
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |